Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dauntless who wrote (352)	10/22/1997 1:11:00 PM
From: Ken Crooks	of 834

Extract from announcement today: TXB announced today the initiation of a Phase IIa study for TBC1269, a non-steroid anti-inflammatory medication for the treatment and prevention of asthma. The Phase IIa trial protocol is designed to evaluate the effects of TBC1269 on pulmonary function as well as drug effects on the immune component of the asthmatic attack. Pre-clinical data has shown that a single dose of this selectin antagonist prevents asthmatic attack in animals. Texas Biotechnology is also conducting a Phase II study of its lead endothelin-A receptor antagonist in congestive heart failure. For additional information, visit the Company's Internet web site at tbc.com .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next